This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
7 Mar 2013

Optimized Basement Membrane Extracts for Organoid Growth and Xenograft Models

AMSBIO announces the availability of two new formulations of Basement Membrane Extract (BME) known as Cultrex BME 2 (organoid growth matrix) and Cultrex BME 3 (xenograft/tumorgraft matrix).

The new products have been developed to address the heterogeneous nature of tissue and organ micro-environments that not only arise from organ specific stromal cells, growth factors, proteoglycans, and protein composition but also from the stiffness or tensile strength of the BME. Many studies have shown that there is a relationship between abnormal tensile strength and both cancer progression and fibrotic tissues. It is both the chemical and physical properties of the BME that are responsible for the mechanical and biological properties of tissues and organs. It was in light of this heterogeneity that Cultrex BME 2 and Cultrex BME 3 were developed.

BME 2 is based upon a proprietary formulation that is higher in tensile strength than original Matrigel or Cultrex BME. This growth factor reduced product is recommended for organoid growth applications including 3D cell culture from stem cells. By comparison, BME 3 has been developed to be physiologically aligned with the in vivo tumour environment and is recommended for xenografts, tumorgrafts and other in vivo applications.

Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma. Basement membranes are degraded and regenerated during development and wound repair. They not only support cells and cell layers, but they also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. Basement membranes provide major barriers to invasion by metastatic tumour cells. Cultrex BME is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumours. The extract gels at 37 °C to form a reconstituted basement membrane. The major components of BME include laminin, collagen IV, entactin, and heparin sulphate proteoglycan. BME can be used for growth promotion or for the differentiation of precursor cells, under a variety of cell culture conditions, involving primary epithelial, endothelial and smooth muscle cells. BME has also been employed in cell attachment, neurite outgrowth, angiogenesis assays, in vitro cell invasion and in vivo tumorigenicity assays.

For further information on Cultrex BME 2 and Cultrex BME 3  please visit
https://www.amsbio.com/Organoid-Growth-Matrix-Xenograft-ECM.aspx or contact AMSBIO now on +44 1235 828 200/+1 949 768 8365 or email [email protected].

 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.